{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:29:56Z","timestamp":1748971796254,"version":"3.37.3"},"reference-count":63,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2020,9]]},"abstract":"Abstract<\/jats:title>\n Introduction The objective of this study was the evaluation of utility of\n plasma level monitoring in the clinical stabilizing efficacy and tolerability of\n paliperidone palmitate (PP) vs. aripiprazole monohydrate (AM) in bipolar\n disorder I (BD I) with manic predominance.<\/jats:p>\n Methods Fifty-six outpatients of both sexes, age ranging from 18 to 65\n years, affected by BD I with manic predominance, orally treated and stabilized\n after acute episode for at least 2 weeks with paliperidone or aripiprazole\n (n=31, paliperidone; n=25, aripiprazole) underwent a prospective\n observational study of switching to the corresponding long-acting injection\n (LAI) on the basis of clinical evaluation. The efficacy and tolerability of the\n 2 treatments were assessed by BPRS, PANSS, HAMD21, and MRS rating scales and a\n check list every month for 12 months. Drug plasma levels determinations (PLs)\n were performed at the same times.<\/jats:p>\n Results A good clinical stability and tolerability of both drugs were\n reported. Lower mean PLs of PP showed a positive effect on depressive symptoms.\n AM PLs variability was associated with greater instability of manic symptoms\n whereas intermediate PLs seem to have more influence on depressive\n symptomatology.<\/jats:p>\n Discussion PLs drug monitoring has been proven to be useful, and further\n investigations to identify optimal therapeutic ranges for LAI formulations are\n needed.<\/jats:p>","DOI":"10.1055\/a-1113-7862","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T00:00:38Z","timestamp":1583884838000},"page":"209-219","source":"Crossref","is-referenced-by-count":12,"title":["Paliperidone LAI and Aripiprazole LAI Plasma Level Monitoring in the\n Prophylaxis of Bipolar Disorder Type I with Manic Predominance"],"prefix":"10.1055","volume":"53","author":[{"given":"Massimo Carlo","family":"Mauri","sequence":"additional","affiliation":[{"name":"Department of Neurosciences and Mental Health, Fondazione IRCCS\n Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"Department of Neurosciences and Mental Health, Psychopharmacology Unit,\n Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan,\n Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Reggiori","sequence":"additional","affiliation":[{"name":"Department of Neurosciences and Mental Health, Fondazione IRCCS\n Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"Department of Neurosciences and Mental Health, Psychopharmacology Unit,\n Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan,\n Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8974-289X","authenticated-orcid":false,"given":"Alessandro","family":"Minutillo","sequence":"additional","affiliation":[{"name":"Department of Neurosciences and Mental Health, Fondazione IRCCS\n Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"Department of Neurosciences and Mental Health, Psychopharmacology Unit,\n Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan,\n Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Franco","sequence":"additional","affiliation":[{"name":"Department of Neurosciences and Mental Health, Fondazione IRCCS\n Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"Department of Neurosciences and Mental Health, Psychopharmacology Unit,\n Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan,\n Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara Di","family":"Pace","sequence":"additional","affiliation":[{"name":"Department of Neurosciences and Mental Health, Fondazione IRCCS\n Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"Department of Neurosciences and Mental Health, Psychopharmacology Unit,\n Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan,\n Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Paletta","sequence":"additional","affiliation":[{"name":"Department of Neurosciences and Mental Health, Fondazione IRCCS\n Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"Department of Neurosciences and Mental Health, Psychopharmacology Unit,\n Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan,\n Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"Unit of Clinical Pharmacology, L. Sacco University Hospital, Milano,\n Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,3,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archgenpsychiatry.2011.12","article-title":"Prevalence and correlates of bipolar spectrum disorder in the World Mental\n Health Survey Initiative","volume":"68","author":"K R Merikangas","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00406-011-0196-4","article-title":"An epidemiologic and clinical overview of medical and psychopathological\n comorbidities in major psychoses","volume":"261","author":"A C Altamura","year":"2011","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.22365\/jpsych.2016.273.182","article-title":"Clinical and cognitive factors affecting psychosocial functioning in remitted\n patients with bipolar disorder","volume":"27","author":"G Konstantakopoulos","year":"2016","journal-title":"Psychiatriki"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/pcn.12463","article-title":"Cognitive dysfunction in major depression and bipolar disorder: assessment and\n treatment options","volume":"71","author":"G M MacQueen","year":"2017","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1001\/archpsyc.1994.03950010008002","article-title":"Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the\n United States: results from the National Comorbidity Survey","volume":"51","author":"R C Kessler","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3109\/10398562.2011.610505","article-title":"The validity and utility of risk assessment for inpatient suicide","volume":"19","author":"M Large","year":"2011","journal-title":"Australas Psychiatry"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.psc.2015.09.002","article-title":"Suicide behaviors in bipolar disorder: a review and update for the\n clinician","volume":"39","author":"J L Beyer","year":"2016","journal-title":"Psychiatr Clin North Am"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4103\/0019-5545.117145","article-title":"Bereavement after the suicide of a significant other","volume":"55","author":"M Pompili","year":"2013","journal-title":"Indian J Psychiatry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2217\/npy.10.2","article-title":"Duration of illness and duration of untreated illness in relation to drug\n response in psychiatric disorders","volume":"1","author":"A C Altamura","year":"2011","journal-title":"Neuropsychiatry (London)"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000338608","article-title":"Can long-term outcomes be improved by shortening the duration of untreated\n illness in psychiatric disorders? A conceptual framework","volume":"46","author":"B Dell\u2019Osso","year":"2012","journal-title":"Psychopathology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/acps.12503","article-title":"Predominant polarity in bipolar disorders: refining or redefining\n diagnosis?","volume":"132","author":"F Colom","year":"2015","journal-title":"Acta Psychiatr Scand"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jad.2006.01.032","article-title":"Clinical and therapeutic implications of predominant polarity in bipolar\n disorder","volume":"93","author":"F Colom","year":"2006","journal-title":"J Affect Disord"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1600-0447.2011.01818.x","article-title":"Predominant recurrence polarity among 928 adult international bipolar I disorder\n patients","volume":"125","author":"R J Baldessarini","year":"2012","journal-title":"Acta Psychiatr Scand"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyu079","article-title":"Treatment implications of predominant polarity and the polarity index: a\n comprehensive review","volume":"18","author":"A F Carvalho","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4088\/JCP.16m11201","article-title":"Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of\n bipolar I disorder","volume":"78","author":"J R Calabrese","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"ref17","first-page":"3111","article-title":"Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review\n of meta-analyses","volume":"11","author":"B Bortolato","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1399-5618.2010.00835.x","article-title":"Effects of recurrence on the cognitive performance of patients with bipolar I\n disorder: implications for relapse prevention and treatment adherence","volume":"12","author":"C L\u00f3pez-Jaramillo","year":"2010","journal-title":"Bipolar Disord"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1399-5618.2005.00207.x","article-title":"Functional impairment in the remission phase of bipolar disorder","volume":"7","author":"A Fagiolini","year":"2005","journal-title":"Bipolar Disord"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1399-5618.2009.00698.x","article-title":"Clinical predictors of functional outcome of bipolar patients in remission","volume":"11","author":"A R Rosa","year":"2009","journal-title":"Bipolar Disord"},{"key":"ref21","first-page":"1","article-title":"Practice guideline for the treatment of patients with bipolar disorder, second\n edition","volume":"159","author":"RM A Hirschfeld","year":"2002","journal-title":"APA Pract Guidel"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1744-859X-8-7","article-title":"The relationship between antipsychotic medication adherence and patient outcomes\n among individuals diagnosed with bipolar disorder: a retrospective study","volume":"8","author":"M J Lage","year":"2009","journal-title":"Ann Gen Psychiatry"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.4088\/JCP.08m04408","article-title":"Treatment nonadherence and neurocognitive impairment in bipolar disorder","volume":"70","author":"A Martinez-Aran","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4088\/JCP.09m05514yel","article-title":"Clinical features associated with poor pharmacologic adherence in bipolar\n disorder","volume":"71","author":"R H Perlis","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"S 04","key":"ref25","first-page":"1","article-title":"The expert consensus guideline series: adherence problems in patients with\n serious and persistent mental illness","volume":"70","author":"D I Velligan","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology:\n update 2017","volume":"51","author":"C Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of\n 29,823 patients with schizophrenia","volume":"74","author":"J Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","article-title":"A nationwide cohort study of oral and depot antipsychotics after first\n hospitalization for schizophrenia","volume":"168","author":"J Tiihonen","year":"2011","journal-title":"Am J Psychiatry"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","article-title":"Long-acting injectable risperidone for relapse prevention and control of\n breakthrough symptoms after a recent first episode of schizophrenia a randomized\n clinical trial","volume":"72","author":"K L Subotnik","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14737175.2017.1371014","article-title":"Long-acting injectable antipsychotics update: lengthening the dosing interval\n and expanding the diagnostic indications","volume":"17","author":"L Citrome","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-244X-7-40","article-title":"Atypical antipsychotics in bipolar disorder: systematic review of randomised\n trials","volume":"7","author":"S Derry","year":"2007","journal-title":"BMC Psychiatry"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/11631310-000000000-00000","article-title":"Long-acting injectable antipsychotics for the maintenance treatment of bipolar\n disorder","volume":"26","author":"A D Gigante","year":"2012","journal-title":"CNS Drugs"},{"key":"ref33","first-page":"3","article-title":"The use of long-acting injectable antipsychotics in Schizophrenia: evaluating\n the evidence","volume":"77","author":"P M Correll CU Haddad","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3111\/13696998.2013.804411","article-title":"Hospitalisation rates in patients switched from oral anti-psychotics to\n aripiprazole once-monthly for the management of schizophrenia","volume":"16","author":"J M Kane","year":"2013","journal-title":"J Med Econ"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40120-015-0030-4","article-title":"Paliperidone palmitate for schizoaffective disorder: A review of the clinical\n evidence","volume":"4","author":"W M Greenberg","year":"2015","journal-title":"Neurol Ther"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/acps.12468","article-title":"Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial\n comparing aripiprazole olanzapine and haloperidol","volume":"133","author":"A Parabiaghi","year":"2016","journal-title":"Acta Psychiatr Scand"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1586\/14737175.2013.811984","article-title":"New second-generation long-acting injectable antipsychotics for the treatment of\n schizophrenia","volume":"13","author":"L Citrome","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1742-1241.2009.02240.x","article-title":"Paliperidone palmitate \u2013 review of the efficacy, safety and cost of a\n new second-generation depot antipsychotic medication","volume":"64","author":"L Citrome","year":"2010","journal-title":"Int J Clin Pract"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2165\/11584270-000000000-00000","article-title":"Aripiprazole in acute mania and long-term treatment of bipolar disorder","volume":"30","author":"P De Fazio","year":"2010","journal-title":"Clin Drug Investig"},{"volume-title":"SCID-5-CV. Intervista Clinica Strutturata per i Disturbi Del DSM-5","year":"2017","author":"M B First","key":"ref44"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale. 1962","volume":"10","author":"J E Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"S Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0447.1986.tb10903.x","article-title":"5.2. Hamilton Depression Scale (HDS) with Melancholia Scale (MES)","volume":"73","author":"M C Hamilton","year":"1986","journal-title":"Acta Psychiatr Scand"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"R C Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0037-1601396","article-title":"Paliperidone long-acting plasma level monitoring and a new method of evaluation\n of clinical stability","volume":"50","author":"M C Mauri","year":"2017","journal-title":"Pharmacopsychiatry"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2147\/NDT.S129559","article-title":"Spotlight on once-monthly long-acting injectable aripiprazole and its potential\n as maintenance treatment for bipolar I disorder in adult patients","volume":"14","author":"V Torres-Llenza","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4088\/JCP.16m11201","article-title":"Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of\n bipolar i disorder: A double-blind, placebo-controlled, 52-week randomized\n withdrawal study","volume":"78","author":"J R Calabrese","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"ref52","first-page":"1002","article-title":"A double-blind study of paliperidone palmitate and risperidon long-acting\n injectable in adults with schizonphrenia. Prog Neuro-Psychopharmacology","volume":"35","author":"G Pandina","year":"2010","journal-title":"Biol Psychiatry"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145711001076","article-title":"A randomized trial of paliperidone palmitate and risperidone long-acting\n injectable in schizophrenia","volume":"15","author":"W W Fleischhacker","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.schres.2015.07.007","article-title":"Qualify: A randomized head-to-head study of aripiprazole once-monthly and\n paliperidone palmitate in the treatment of schizophrenia","volume":"168","author":"D Naber","year":"2015","journal-title":"Schizophr Res"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"27208","DOI":"10.3402\/jmahp.v3.27208","article-title":"Efficacy, tolerability, and safety of aripiprazole once-monthly vs. other\n long-acting injectable antipsychotic therapies in the maintenance treatment of\n schizophrenia: a mixed treatment comparison of double-blind randomized clinical\n trials","volume":"3","author":"I M Majer","year":"2015","journal-title":"J Mark Access Heal Policy"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/14740338.2017.1288716","article-title":"Paliperidone for the treatment of schizophrenia and schizoaffective disorders\n \u2013 a drug safety evaluation","volume":"16","author":"M C Mauri","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","article-title":"Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in\n patients with schizophrenia: A randomized, double-blind, placebo-controlled\n study","volume":"116","author":"D Hough","year":"2010","journal-title":"Schizophr Res"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","article-title":"A randomized, placebo-controlled study to assess the efficacy and safety of 3\n doses of paliperidone palmitate in adults with acutely exacerbated\n schizophrenia","volume":"30","author":"G J Pandina","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1017\/S1461145709990988","article-title":"Paliperidone palmitate, a potential long-acting treatment for patients with\n schizophrenia. Results of a randomized, double-blind, placebo-controlled\n efficacy and safety study","volume":"13","author":"M Kramer","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-244X-12-26","article-title":"A one-year prospective study of the safety, tolerability and pharmacokinetics of\n the highest available dose of paliperidone palmitate in patients with\n schizophrenia","volume":"12","author":"D Coppola","year":"2012","journal-title":"BMC Psychiatry"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/NDT.S77778","article-title":"Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in\n recent-onset schizophrenia","volume":"11","author":"F Zhang","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref62","first-page":"1163","article-title":"Clinical pharmacology of atypical antipsychotics: an update","volume":"13","author":"M C Mauri","year":"2014","journal-title":"Excli J"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1185\/03007995.2013.821973","article-title":"Safety and tolerability of once monthly aripiprazole treatment initiation in\n adults with schizophrenia stabilized on selected atypical oral antipsychotics\n other than aripiprazole","volume":"29","author":"S G Potkin","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s40262-018-0664-3","article-title":"Clinical pharmacokinetics of atypical antipsychotics: an Update","volume":"57","author":"M C Mauri","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in\n psychiatry","volume":"37","author":"P Baumann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.12740\/PP\/65307","article-title":"Therapeutic drug monitoring of atypical antipsychotics","volume":"51","author":"A Urban","year":"2017","journal-title":"Psychiatr Pol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2147\/NDT.S133433","article-title":"Plasma concentrations and dosing of 2 long-acting injectable formulations of\n aripiprazole","volume":"13","author":"P M Salzman","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/JCP.0000000000000913","article-title":"Intraindividual and interindividual variability of olanzapine trough\n concentrations in patients treated with the long-acting injectable\n formulation","volume":"38","author":"S Baldelli","year":"2018","journal-title":"J Clin Psychopharmacol"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1113-7862.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T22:45:57Z","timestamp":1599173157000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1113-7862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,10]]},"references-count":63,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2020,9,3]]},"published-print":{"date-parts":[[2020,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1113-7862","relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"type":"print","value":"0176-3679"},{"type":"electronic","value":"1439-0795"}],"subject":[],"published":{"date-parts":[[2020,3,10]]}}}